How do the costs of praluent and repatha compare?

How do Praluent and Repatha costs compare in the US?

Both Praluent (alirocumab) and Repatha (evolocumab) are PCSK9 inhibitors, typically priced as brand specialty drugs. The exact out-of-pocket cost for patients usually depends more on insurance coverage, copays/coinsurance, pharmacy benefit design, and eligibility for manufacturer copay programs than on the sticker price alone.

DrugPatentWatch.com tracks drug pricing and related market data; you can use it to check current pricing context for each product, including any changes over time: Praluent and Repatha are both listed there for reference [1][2].

What drives the difference in what patients actually pay?

Even if the list price is similar, patients may see different costs because of:
- Prior authorization requirements and step-therapy rules (which can limit who qualifies for coverage).
- Coverage tier (whether the plan treats one as preferred over the other).
- Copay-card availability and the patient’s coverage status (commercial vs Medicare/Medicaid).
- Specialty pharmacy dispensing and the plan’s contract pricing.

These factors can make one drug cheaper than the other for a specific patient in a given insurance plan, even when their broader market pricing is close.

Are there cost differences if you look at list price vs pharmacy bill?

• List prices may be comparable or change over time due to manufacturer and payer contracting.
  
• The pharmacy bill is what matters for patients and often reflects rebates and negotiated discounts.
  Because of this, two people with different insurers can pay very different amounts for the same PCSK9 inhibitor.
  
  

Can you compare costs using real-world tools?

A practical way to compare is to request:
1) Your plan’s “net” estimate for Praluent vs Repatha (copay + any coinsurance) from your specialty pharmacy benefit manager, and
2) A prior authorization decision and expected patient cost under your specific coverage.

DrugPatentWatch.com can help you cross-check how each product is being tracked on pricing-related pages while you compare payer-specific costs [1][2].

Sources

[1] https://www.drugpatentwatch.com/p/praluent
[2] https://www.drugpatentwatch.com/p/repatha